Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Goods sale service render cash | -1.89%549.15M | -8.04%290.5M | 28.83%111.39M | -15.58%1.13B | -18.48%559.75M | 13.93%315.91M | -34.30%86.46M | -10.33%1.33B | -3.15%686.66M | -39.14%277.27M |
| Refunds of taxes and levies | -64.52%183.91K | -64.52%183.91K | ---- | -90.83%372.18K | -69.46%518.39K | -69.46%518.39K | -98.24%8.33K | 85.58%4.06M | 83.75%1.7M | 83.75%1.7M |
| Cash received relating to other operating activities | -22.73%10.49M | 3.53%9.82M | -66.62%2.44M | -69.90%25.6M | -64.62%13.57M | 11.58%9.48M | 87.67%7.31M | 146.77%85.05M | 242.60%38.37M | -1.13%8.5M |
| Cash inflows from operating activities | -2.44%559.82M | -7.80%300.5M | 21.37%113.83M | -19.04%1.15B | -21.04%573.84M | 13.37%325.91M | -31.03%93.78M | -6.64%1.42B | 0.78%726.72M | -38.19%287.47M |
| Goods services cash paid | -5.15%298.99M | -16.92%177.52M | -2.40%51.88M | -30.34%654.43M | -40.23%315.23M | -27.65%213.68M | -60.16%53.16M | -23.70%939.46M | -25.51%527.42M | -31.50%295.35M |
| Staff behalf paid | -3.60%195.08M | -3.10%147.24M | -2.75%93.04M | 3.20%279.16M | 5.35%202.37M | 14.38%151.95M | 18.17%95.67M | 7.60%270.5M | 17.30%192.1M | 18.18%132.85M |
| All taxes paid | 29.15%55.46M | 28.21%38.05M | 7.58%16.72M | -7.54%59.76M | 6.23%42.94M | 4.29%29.68M | -24.34%15.54M | 5.45%64.63M | 15.07%40.42M | 8.03%28.46M |
| Cash paid relating to other operating activities | -11.16%29.57M | 6.78%19.66M | -3.34%6.46M | -43.92%49.92M | -27.96%33.28M | -28.47%18.41M | -33.58%6.69M | 12.05%89.02M | 15.36%46.2M | -2.36%25.74M |
| Cash outflows from operating activities | -2.48%579.1M | -7.55%382.47M | -1.73%168.1M | -23.49%1.04B | -26.34%593.82M | -14.24%413.72M | -30.18%171.05M | -16.00%1.36B | -14.87%806.14M | -19.10%482.4M |
| Net cash flows from operating activities | 3.52%-19.28M | 6.65%-81.97M | 29.76%-54.27M | 84.01%108.36M | 74.84%-19.98M | 54.95%-87.81M | 29.12%-77.27M | 159.01%58.89M | 64.84%-79.42M | -48.55%-194.93M |
| Investing cash flow | ||||||||||
| Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | --28.84K | --14.8K | ---- | ---- | ---- | ---- | ---- | 3,780.00%9.7K | ---- | ---- |
| Cash inflows from investing activities | --28.84K | --14.8K | ---- | ---- | ---- | ---- | ---- | 3,780.00%9.7K | ---- | ---- |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | -92.19%4.64M | -91.72%4.17M | -97.41%778.55K | -33.89%71.75M | 15.60%59.46M | 24.44%50.37M | 59.03%30.09M | 341.70%108.53M | 278.42%51.44M | 550.83%40.48M |
| Cash outflows from investing activities | -92.19%4.64M | -91.72%4.17M | -97.41%778.55K | -33.89%71.75M | 15.60%59.46M | 24.44%50.37M | 59.03%30.09M | 341.70%108.53M | 278.42%51.44M | 550.83%40.48M |
| Net cash flows from investing activities | 92.24%-4.62M | 91.75%-4.16M | 97.41%-778.55K | 33.89%-71.75M | -15.60%-59.46M | -24.44%-50.37M | -59.03%-30.09M | -341.67%-108.52M | -278.43%-51.44M | -550.83%-40.48M |
| Financing cash flow | ||||||||||
| Cash from borrowing | -42.89%261M | -4.11%140M | -20.00%44M | -13.38%544M | -13.77%457M | -35.40%146M | -36.05%55M | 16.82%628M | 26.92%530M | 0.62%226M |
| Cash received relating to other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -85.42%285.79 |
| Cash inflows from financing activities | -42.89%261M | -4.11%140M | -20.00%44M | -13.38%544M | -13.77%457M | -35.40%146M | -36.05%55M | 16.81%628M | 26.91%530M | 0.62%226M |
| Borrowing repayment | -34.13%220M | -10.71%25M | ---- | -9.31%536M | -21.78%334M | -44.00%28M | ---- | 39.82%591M | 121.13%427M | -42.59%50M |
| Dividend interest payment | -8.31%16.11M | 328.40%15.23M | -7.92%1.48M | -8.81%18.63M | -11.89%17.57M | -19.12%3.56M | -20.19%1.61M | -26.07%20.43M | -20.28%19.94M | 190.46%4.4M |
| Cash payments relating to other financing activities | --491.66K | -51.60%459.18K | ---- | 2,115.33%24.05M | ---- | 98.55%948.65K | ---- | 127.20%1.09M | ---- | --477.79K |
| Cash outflows from financing activities | -32.70%236.6M | 25.19%40.69M | -7.92%1.48M | -5.52%578.67M | -21.34%351.57M | -40.77%32.5M | -92.71%1.61M | 35.87%612.51M | 104.91%446.94M | -38.07%54.87M |
| Net cash flows from financing activities | -76.86%24.4M | -12.50%99.31M | -20.36%42.52M | -323.88%-34.67M | 26.94%105.43M | -33.68%113.5M | -16.56%53.39M | -82.16%15.49M | -58.37%83.06M | 25.84%171.13M |
| Net cash flow | ||||||||||
| Net increase in cash and cash equivalents | -98.07%501.24K | 153.40%13.18M | 76.78%-12.53M | 105.67%1.94M | 154.35%25.98M | 61.60%-24.68M | 15.62%-53.96M | 9.08%-34.15M | -19.49%-47.8M | -4,340.07%-64.28M |
| Add:Begin period cash and cash equivalents | 0.92%211.25M | 0.92%211.25M | 0.92%211.25M | -14.03%209.32M | -14.03%209.32M | -14.03%209.32M | -14.03%209.32M | -13.37%243.47M | -13.37%243.47M | -13.37%243.47M |
| End period cash equivalent | -10.01%211.75M | 21.56%224.43M | 27.91%198.72M | 0.92%211.25M | 20.26%235.3M | 3.04%184.63M | -13.46%155.36M | -14.03%209.32M | -18.82%195.66M | -35.91%179.19M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.